Oryzon Genomics - New clinical candidate expands CNS portfolio
Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders including Charcot-Marie-Tooth (CMT) disease and amyotrophic lateral sclerosis (ALS). The decision follows positive data in which ORY 4001 demonstrated both an encouraging selectivity and safety profile as well as efficacy signals, triggering a strong anti-inflammatory response in preclinical in vivo models; the compound also showed positive responses in a validated CMT1A peripheral neuropathy in vivo model, which reliably recapitulates many of the symptoms of this condition in humans. In July 2022, Oryzon collaborated with the CMT Research Foundation, which helped fund the preclinical studies for ORY-4001 in CMT and, in our view, highlights the positive impact Oryzon’s partnerships can have on expediting development. The company now intends to start investigational new drug enabling studies as it progresses ORY-4001 towards clinical trials, the initiation of which would represent a future catalyst for investor attention.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.